Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s New Benchmark For New Era: 8% Annual Growth Is Sustainable

Executive Summary

The pharmaceutical industry is entering a period where average annual growth rates are likely to hover at about 8%, Pfizer CEO Hank McKinnell predicted during a Nov. 30 analyst meeting in Groton, Conn
Advertisement

Related Content

Marginal Profitability Of Mature Products Not What It Used To Be – Pfizer CEO
Personalized Medicine Will Not Destroy Blockbuster Model – Pfizer Exec
AstraZeneca Cuts Sales Reps By Reducing PDI Contract; Will Others Follow?
Pfizer Confident That Caduet Will Succeed; How Safe Is Sales Force?
Pfizer Sees 5% Growth In Second Half; Currency, Competition Hurt Sales
Pfizer Sees 5% Growth In Second Half; Currency, Competition Hurt Sales
“Blockbuster” Launch Model Changing, Pfizer Says; Still Hope For Caduet
Pfizer Caduet Launch Set For May; Inspra Starts Slow
Pfizer Recognizes “Dark Side” Of Scale In R&D; No Sales Force Cuts Planned
Sales Force Bubble May Soon Burst; Slowing R&D Is Cause, Takeda Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS045073

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel